Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Postherpetic Neuralgia Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

NCT05754190
View directory record Official record
Conditions
Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary, Fibromyalgia, Secondary, Fibromyalgia, Irritable Bowel Syndrome, Chronic Headache Disorder, Chronic Migraine, Chronic Pelvic Pain Syndrome, Temporomandibular Joint Disorders, Endometriosis-related Pain, Arthritis, Chronic Low-back Pain, Failed Back Surgery Syndrome, Post Herpetic Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy, Painful Bladder Syndrome, Trauma-related Wound, Trauma, Multiple, Chronic Pain Syndrome, Chronic Shoulder Pain
Interventions
SOMA pain manager smartphone application
Device
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

NCT00612105
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Retigabine, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia

NCT01757873
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Z160, Placebo
Drug
Lead sponsor
Zalicus
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
53
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

NCT01129531
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
AGN-214868, Placebo to AGN-214868
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Jul 21, 2026, 1:02 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of APC101 in Patients With Postherpetic Neuralgia.

NCT07599800
View directory record Official record
Conditions
PHN - Post-Herpetic Neuritis
Interventions
APC101, Control
Drug · Other
Lead sponsor
Andros Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Florida City, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Phase 2Phase 3 Interventional

NGX-4010 for the Treatment of Postherpetic Neuralgia

NCT00061776
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases, Shingles
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

NCT00335933
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
Gabapentin extended-release tablets
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2007 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Phase 2 Interventional

A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)

NCT00576108
View directory record Official record
Conditions
Postherpetic Neuralgia, Shingles, Herpes Zoster, Neuropathic Pain
Interventions
KD7040 Topical Gel, Placebo gel
Drug
Lead sponsor
Kalypsys, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 21, 2008 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment

NCT00617461
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
GEn 1200mg/day, GEn 3600mg/day
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
42
States / cities
Phoenix, Arizona • Oxnard, California • Roseville, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Phase 3 Interventional

Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

NCT00068081
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Jul 21, 2026, 1:02 PM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

NCT01058642
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
ADL5747, Placebo, Pregabalin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

NCT01223365
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydrocodone ER
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
54
States / cities
Mobile, Alabama • Anaheim, California • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Jul 21, 2026, 1:02 PM EDT
Not listed Phase 2 Interventional

Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia

NCT00813826
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
SLC022, Placebo
Drug
Lead sponsor
Solace Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Sierra Vista, Arizona • Mission Viejo, California • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2009 · Synced Jul 21, 2026, 1:02 PM EDT
Active, not recruiting Not applicable Interventional

Transcranial Magnetic Stimulation for Chronic Neuropathic Pain

NCT05593237
View directory record Official record
Conditions
Chronic Neuropathic Pain, Post-Stroke Pain, Trigeminal Neuralgia, Nerve Injury, Spinal Cord Injuries, Pain, Postoperative, Complex Regional Pain Syndromes, Post-herpetic Neuralgia, Nerve Root Avulsion
Interventions
High Frequency rTMS, Low Frequency rTMS
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Not applicable Interventional

Reduction of Postherpetic Neuralgia in Herpes Zoster

NCT01250561
View directory record Official record
Conditions
Herpes Zoster, Post-herpetic Neuralgia
Interventions
Gabapentin, Valacyclovir
Drug
Lead sponsor
Center for Clinical Studies, Texas
Other
Eligibility
50 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2010 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Phase 4 Interventional

A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

NCT00904020
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Low Back Pain
Interventions
Lidoderm
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Plantation, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Phase 2 Interventional

Crossover Post-herpetic Neuralgia (PHN)

NCT01305538
View directory record Official record
Conditions
Post-Herpetic Neuralgia (PHN)
Interventions
BMS-954561, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Phoenix, Arizona • Lomita, California • Boulder, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Phase 4 Interventional

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

NCT00904202
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
Interventions
Placebo Capsules + Placebo Patch, Placebo capsules + Lidoderm®, Gabapentin + Placebo, Gabapentin + Lidoderm®, Gabapentin 300 mg capsules 1800 mg/day + placebo patch, Gabapentin 1800 mg/day + Lidoderm patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Not applicable Interventional Results available

Transcranial Magnetic Stimulation for Facial Pain

NCT02633306
View directory record Official record
Conditions
Trigeminal Nerve Injuries, Post-herpetic Neuralgia, Facial Pain, Nervus Intermedius Neuralgia
Interventions
transcranial magnetic stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 110 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Five Selected Markers in Skin Biopsies of Patients With Postherpetic Neuralgia and Healthy Controls

NCT01379716
View directory record Official record
Conditions
Postherpetic Neuralgia, Healthy Age/Gender Matched Volunteers
Interventions
skin biopsy
Other
Lead sponsor
Albany Medical College
Other
Eligibility
50 Years to 95 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2020 · Synced Jul 21, 2026, 1:02 PM EDT
Completed No phase listed Observational Results available

Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia

NCT01426230
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
Not listed
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
37
States / cities
Mobile, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Not applicable Interventional Results available

Effects of Pennsaid on Clinical Neuropathic Pain

NCT01508676
View directory record Official record
Conditions
Neuralgia, Postherpetic Neuralgia, Reflex Sympathetic Dystrophy, Complex Regional Pain Syndrome (CRPS)
Interventions
Pennsaid, Placebo (2.3% DMSO solution)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Jul 21, 2026, 1:02 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants

NCT07618715
View directory record Official record
Conditions
Healthy Male and Female Subjects
Interventions
Y-4 tablet, Pregabalin capsule, Riluzole tablet
Drug
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 21, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia

NCT04662281
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Placebo, LX9211
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Scottsdale, Arizona • Tucson, Arizona • Greenbrae, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 21, 2026, 1:02 PM EDT